{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T14:35:33Z","timestamp":1771943733631,"version":"3.50.1"},"reference-count":62,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kite pharma\u00ae"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Diffuse large B-cell lymphomas (DLBCLs) are the most common, aggressive disease form that accounts for 30% of all lymphoma cases. Identifying patients who will respond to these advanced cell-based therapies is an unaddressed challenge. Methods: We propose to develop a radiomics- (quantitative image metric) based signature on the patients\u2019 imaging scans (positron emission tomography\/computed tomography, PET\/CT) and use these metrics to prognosticate response to axi-cel (axicabtagene ciloleucel), autologous CD19 chimeric antigen receptor (CAR) T-cell (CAR-T) therapy. We curated a cohort of 155 patients with relapsed\/refractory (R\/R) DLBCL who were treated with axi-cel. Using their baseline image scan (PET\/CT), the largest lesions related to nodal\/extra-nodal disease were identified and characterized using imaging metrics (radiomics). We used principal component (PC) analysis to reduce the dimensionality of these features across the functional categories (size, shape, and texture). We evaluated the prognostic ability of radiomic-based PC to treatment response (1-year), measured by overall survival (OS) and progression-free survival (PFS). Results: We found that radiomic PC was prognostic of overall survival (Shape-PC, q &lt; 0.013\/0.0108, Size-PC, q &lt; 0.003\/0.0088), in CT\/PET, respectively. In comparison, the metabolic tumor volume (MTV) was prognostic (q &lt; 0.0002\/0.0007). The radiomic PCs across the functional categories showed moderate to weak correlation with MTV, Spearman\u2019s \u03c1 of 0.44\/0.35\/0.27, and 0.45\/0.36\/0.55 for Size\/Shape\/Texture-PC1 obtained on PET and CT, respectively. Conclusions: We found radiomic PC based on size and shape metrics that are able to prognosticate treatment response to CAR-T therapy.<\/jats:p>","DOI":"10.3390\/cancers17111832","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T09:22:41Z","timestamp":1748596961000},"page":"1832","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Radiomic Features Prognosticate Treatment Response in CAR-T Cell Therapy"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5598-4727","authenticated-orcid":false,"given":"Yoganand","family":"Balagurunathan","sequence":"first","affiliation":[{"name":"Department of Machine Learning, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA"},{"name":"Department of Diagnostic & Interventional Radiology, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8206-4259","authenticated-orcid":false,"given":"Jung W.","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Diagnostic & Interventional Radiology, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Biostatistics & Bioinformatics, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Blood and Marrow Transplant, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[{"name":"Department of Blood and Marrow Transplant, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2214\/AJR.16.16180","article-title":"Imaging for Oncologic Response Assessment in Lymphoma","volume":"208","author":"Kulkarni","year":"2016","journal-title":"Am. J. Roentgenol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ejh.13863","article-title":"The diagnosis and management of suspected lymphoma in general practice","volume":"110","author":"Paquin","year":"2023","journal-title":"Eur. J. Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma (1997). The Non-Hodgkin\u2019s Lymphoma Classification Project. Blood, 89, 3909\u20133918.","DOI":"10.1182\/blood.V89.11.3909"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/bjh.15789","article-title":"Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma","volume":"185","author":"Metzger","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ajh.26151","article-title":"2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management","volume":"96","author":"Barta","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.3324\/haematol.2023.284070","article-title":"The International Prognostic Index in aggressive B-cell lymphoma","volume":"108","author":"Maurer","year":"2023","journal-title":"Haematologica"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project (1993). A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N. Engl. J. Med., 329, 987\u2013994.","DOI":"10.1056\/NEJM199309303291402"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1148\/radiol.2015142088","article-title":"Imaging for Staging and Response Assessment in Lymphoma","volume":"276","author":"Johnson","year":"2015","journal-title":"Radiology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1182\/blood.2019003526","article-title":"High total metabolic tumor volume at baseline predicts survival independent of response to therapy","volume":"135","author":"Vercellino","year":"2020","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/bloodadvances.2021005385","article-title":"Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma","volume":"6","author":"Voorhees","year":"2022","journal-title":"Blood Adv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.blre.2016.06.003","article-title":"Clinical approach to diffuse large B cell lymphoma","volume":"30","author":"Caimi","year":"2016","journal-title":"Blood Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1038\/ncomms5006","article-title":"Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach","volume":"5","author":"Aerts","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e23421","DOI":"10.7554\/eLife.23421","article-title":"Defining the biological basis of radiomic phenotypes in lung cancer","volume":"6","author":"Grossmann","year":"2017","journal-title":"Elife"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.mri.2012.06.010","article-title":"Radiomics: The process and the challenges","volume":"30","author":"Kumar","year":"2012","journal-title":"Magn. Reson. Imaging"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/jha2.757","article-title":"PET-based radiomics signature can predict durable responses to CAR T-cell therapy in patients with large B-cell lymphoma","volume":"4","author":"Ligero","year":"2023","journal-title":"eJHaem"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Balagurunathan, Y., Wei, Z., Qi, J., Thompson, Z., Dean, E., Lu, H., Vardhanabhuti, S., Corallo, S., Choi, J.W., and Kim, J.J. (2024). Radiomic Features on PET\/CT Imaging of Large B cell Lymphoma Lesions Predicts CAR T-cell Therapy Efficacy. Front. Oncol. Sect. Hematol. Malig., 14.","DOI":"10.3389\/fonc.2024.1485039"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1148\/radiol.2016142043","article-title":"Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0","volume":"280","author":"O","year":"2016","journal-title":"Radiology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2967\/jnumed.115.166280","article-title":"Response Assessment Criteria and Their Applications in Lymphoma: Part 1","volume":"57","author":"Moghbel","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1593\/tlo.13844","article-title":"Reproducibility and Prognosis of Quantitative Features Extracted from CT Images","volume":"7","author":"Balagurunathan","year":"2014","journal-title":"Transl. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s10278-014-9716-x","article-title":"Test-retest reproducibility analysis of lung CT image features","volume":"27","author":"Balagurunathan","year":"2014","journal-title":"J. Digit. Imaging"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1148\/radiol.2020191145","article-title":"The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping","volume":"295","author":"Zwanenburg","year":"2020","journal-title":"Radiology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1136\/bmj.328.7447.1073","article-title":"The logrank test","volume":"328","author":"Bland","year":"2004","journal-title":"BMJ Clin. Res. Ed."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J. R. Stat. Soc. Ser. B Methodol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/sim.4154","article-title":"On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data","volume":"30","author":"Uno","year":"2011","journal-title":"Stat. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"9440","DOI":"10.1073\/pnas.1530509100","article-title":"Statistical significance for genomewide studies","volume":"100","author":"Storey","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13045-024-01540-x","article-title":"Conventional and novel [(18)F]FDG PET\/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma","volume":"17","author":"Leithner","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2214\/AJR.09.3665","article-title":"Characterization of T-cell lymphomas by FDG PET\/CT","volume":"195","author":"Feeney","year":"2010","journal-title":"AJR. Am. J. Roentgenol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Wang, S., Chen, A., Yang, L., Cai, L., Xie, Y., Fujimoto, J., Gazdar, A., and Xiao, G. (2018). Comprehensive analysis of lung cancer pathology images to discover tumor shape and boundary features that predict survival outcome. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-27707-4"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Grove, O., Berglund, A.E., Schabath, M.B., Aerts, H.J., Dekker, A., Wang, H., Velazquez, E.R., Lambin, P., Gu, Y., and Balagurunathan, Y. (2015). Quantitative computed tomographic descriptors associate tumor shape complexity and intratumor heterogeneity with prognosis in lung adenocarcinoma. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0118261"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Palumbo, B., Bianconi, F., Palumbo, I., Fravolini, M.L., Minestrini, M., Nuvoli, S., Stazza, M.L., Rondini, M., and Spanu, A. (2020). Value of Shape and Texture Features from 18F-FDG PET\/CT to Discriminate between Benign and Malignant Solitary Pulmonary Nodules: An Experimental Evaluation. Diagnostics, 10.","DOI":"10.3390\/diagnostics10090696"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.crad.2019.04.017","article-title":"Artificial intelligence and radiomics in pulmonary nodule management: Current status and future applications","volume":"75","author":"Ather","year":"2020","journal-title":"Clin. Radiol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Balagurunathan, Y., Schabath, M.B., Wang, H., Liu, Y., and Gillies, R.J. (2019). Quantitative Imaging features Improve Discrimination of Malignancy in Pulmonary nodules. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-44562-z"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"041001","DOI":"10.1117\/1.JMI.2.4.041001","article-title":"Special Section Guest Editorial:Radiomics and Imaging Genomics: Quantitative Imaging for Precision Medicine","volume":"2","author":"Napel","year":"2015","journal-title":"J. Med. Imaging"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3174\/ajnr.A5391","article-title":"Radiomics in Brain Tumor: Image Assessment, Quantitative Feature Descriptors, and Machine-Learning Approaches","volume":"39","author":"Zhou","year":"2018","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Levstek, L., Jan\u017ei\u010d, L., Ihan, A., and Kopitar, A.N. (2024). Biomarkers for prediction of CAR T therapy outcomes: Current and future perspectives. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1378944"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.annonc.2020.11.019","article-title":"Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET\/CT(\u2020)","volume":"32","author":"Cottereau","year":"2021","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40170-021-00244-x","article-title":"Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative (18)F-FDG PET\/CT in patients with localized primary gastrointestinal stromal tumors","volume":"9","author":"Hwang","year":"2021","journal-title":"Cancer Metab."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1007\/s00259-018-3953-z","article-title":"Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma","volume":"45","author":"Ilyas","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood.2020005112","article-title":"Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era","volume":"137","author":"Bobillo","year":"2021","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/ejh.13968","article-title":"Response rates of extra-nodal diffuse large B cell lymphoma to anti-CD19-CAR T cells: A real word retrospective multicenter study","volume":"111","author":"Perry","year":"2023","journal-title":"Eur. J. Haematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.clon.2015.11.011","article-title":"Prognosis, Treatment Benefit and Goals of Care: What do Oncologists Discuss with Patients who have Incurable Cancer?","volume":"28","author":"Raskin","year":"2016","journal-title":"Clin. Oncol. R. Coll. Radiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/0825859718762287","article-title":"Perceived Barriers to Goals of Care Discussions With Patients With Advanced Cancer and Their Families in the Ambulatory Setting: A Multicenter Survey of Oncologists","volume":"33","author":"Ethier","year":"2018","journal-title":"J. Palliat. Care"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.diii.2013.12.014","article-title":"Solid masses: What are the underlying histopathological lesions?","volume":"95","year":"2014","journal-title":"Diagn. Interv. Imaging"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"232","DOI":"10.21037\/qims.2018.03.03","article-title":"CT and MRI of superficial solid tumors","volume":"8","author":"Zhang","year":"2018","journal-title":"Quant. Imaging Med. Surg."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/bloodadvances.2020001816","article-title":"High metabolic heterogeneity on baseline 18FDG-PET\/CT scan as a poor prognostic factor for newly diagnosed diffuse large B-cell lymphoma","volume":"4","author":"Senjo","year":"2020","journal-title":"Blood Adv."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1158\/2643-3230.BCD-24-0052","article-title":"A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas","volume":"5","author":"Stella","year":"2024","journal-title":"Blood Cancer Discov."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"9761","DOI":"10.1182\/blood-2022-165179","article-title":"High Expression of Plasma IL-1\u03b2 Levels and Transition of Regulatory T-Cell Subsets Correlate with Disease Progression in Myelodysplastic Syndrome","volume":"140","author":"Zhang","year":"2022","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"6455","DOI":"10.1182\/blood-2023-183057","article-title":"High Serum ST2 Level Predicts Progression and Poor Prognosis of Denovomyelodysplastic Syndrome","volume":"142","author":"Peng","year":"2023","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Gong, Y., Fei, P., Zhang, Y., Xu, Y., and Wei, J. (2025). From Multi-Omics to Visualization and Beyond: Bridging Micro and Macro Insights in CAR-T Cell Therapy. Adv. Sci., e2501095.","DOI":"10.1002\/advs.202501095"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1158\/2643-3230.BCD-23-0240","article-title":"Advancing CAR T-cell Therapies with Artificial Intelligence: Opportunities and Challenges","volume":"6","author":"Luciani","year":"2025","journal-title":"Blood Cancer Discov."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Shahzadi, M., Rafique, H., Waheed, A., Naz, H., Waheed, A., Zokirova, F.R., and Khan, H. (2024). Artificial intelligence for chimeric antigen receptor-based therapies: A comprehensive review of current applications and future perspectives. Ther. Adv. Vaccines Immunother., 12.","DOI":"10.1177\/25151355241305856"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejmp.2021.02.024","article-title":"Requirements and reliability of AI in the medical context","volume":"83","author":"Balagurunathan","year":"2021","journal-title":"Phys. Medica"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1057\/s41599-024-04044-8","article-title":"Trust in AI: Progress, challenges, and future directions","volume":"11","author":"Afroogh","year":"2024","journal-title":"Humanit. Social. Sci. Commun."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/11\/1832\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:44:03Z","timestamp":1760031843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/11\/1832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":62,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["cancers17111832"],"URL":"https:\/\/doi.org\/10.3390\/cancers17111832","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]}}}